Provider Briefing: Adempas Availability in 2026

For clinicians managing patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), access to Adempas (Riociguat) remains a critical concern. While there is no official FDA-listed shortage of Adempas as of early 2026, the medication's REMS-restricted distribution, specialty pharmacy requirements, and insurance complexities continue to create access barriers that directly affect patient outcomes.

This briefing provides an up-to-date overview of Adempas availability, prescribing considerations, cost landscape, and tools to help your patients maintain uninterrupted therapy.

Timeline: Adempas Regulatory and Market History

• October 2013: FDA approval of Adempas (Riociguat) for CTEPH and PAH (WHO Group 1)
• 2013-present: Distributed exclusively through the Adempas REMS program due to embryo-fetal toxicity risk
• 2021: Updated labeling to include combination therapy data with ERAs and prostacyclin analogs for PAH
• 2024-2025: FDA approval of generic Riociguat, though commercial launch has not yet occurred
• 2025: Medicare Part D out-of-pocket cap of $2,000 implemented under the Inflation Reduction Act, potentially reducing cost burden for Medicare patients

Prescribing Implications

REMS Enrollment Requirements

Prescribers must be enrolled in the Adempas REMS program to write prescriptions for Riociguat. This includes:

• Completing REMS certification through the Adempas REMS website (adempasrems.com)
• Ensuring female patients of reproductive potential have documented negative pregnancy tests prior to initiation, monthly during therapy, and one month after discontinuation
• Counseling patients on the requirement for two forms of contraception
• Completing and signing patient enrollment forms

Prescribers who are not REMS-certified cannot prescribe Adempas. If you refer patients to PH specialists, confirm that the receiving provider is REMS-enrolled before transfer of care.

Dosing Considerations

Adempas is initiated at 1 mg TID and titrated by 0.5 mg increments every 2 weeks based on systolic blood pressure (maintain SBP ≥95 mmHg) to a maximum of 2.5 mg TID. Key clinical considerations:

• Smokers may require higher doses due to increased CYP1A1 activity. Consider dose reduction if the patient quits smoking during therapy.
• Strong CYP/P-gp/BCRP inhibitors (ketoconazole, ritonavir): Consider starting dose of 0.5 mg TID and monitor for hypotension.
• Antacids containing aluminum hydroxide or magnesium hydroxide should be separated by at least 1 hour from Adempas dosing.

For complete dosing details, see our clinical overview at Adempas uses and dosage.

Critical Contraindications

Ensure documentation and patient awareness of absolute contraindications:

• Pregnancy — embryo-fetal toxicity (boxed warning)
• Concomitant PDE-5 inhibitors — Sildenafil (Revatio), Tadalafil (Adcirca/Cialis), Vardenafil (Levitra). Risk of severe hypotension.
• Nitrates and nitric oxide donors — nitroglycerin, isosorbide dinitrate/mononitrate, amyl nitrite. Risk of life-threatening hypotension.
• Nonspecific PDE inhibitors — dipyridamole, theophylline

A complete interaction reference is available at Adempas drug interactions.

Current Availability Picture

The supply of Adempas from Bayer remains stable. There is no active FDA drug shortage listing for Riociguat. However, practical access challenges persist:

• Limited pharmacy network: Only REMS-certified specialty pharmacies can dispense. Most retail pharmacies cannot fill Adempas prescriptions.
• Insurance gatekeeping: Prior authorization is required by most commercial and Medicare plans. Step therapy requirements may delay access.
• Specialty pharmacy bottlenecks: Processing times of 5-10 business days for initial fills are common due to REMS compliance verification, insurance PA, and patient enrollment coordination.

Providers can help by initiating the specialty pharmacy referral at the time of prescribing, rather than leaving patients to navigate the process independently.

Cost and Access Landscape

Adempas remains a high-cost specialty medication:

• Cash price: ~$14,000-$15,000/month (90 tablets at ~$161/tablet)
• Commercial insurance: Specialty tier copays/coinsurance typically apply. Bayer's Aim copay assistance may cover up to 100% of out-of-pocket costs for eligible commercially insured patients.
• Medicare Part D: Covered under specialty tier. The $2,000 annual out-of-pocket cap (IRA 2025) may limit patient burden.
• Uninsured patients: Bayer US Patient Assistance Foundation provides free medication to qualifying patients.

Generic Riociguat Status

The FDA has approved generic Riociguat, but it is not yet commercially available as of Q1 2026. When launched, generic availability may ease cost pressure but will still require REMS-compliant distribution.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool to check real-time pharmacy availability for Adempas and other specialty medications. Share this resource with your clinical team and patients to reduce time spent on phone calls to pharmacies.

Bayer Aim Patient Support Program

The Aim program (855-423-3672) provides:

• Specialty pharmacy coordination
• Insurance prior authorization support
• Copay assistance for commercially insured patients
• Free drug program referrals for uninsured patients

Patient Assistance Foundations

• Patient Access Network (PAN) Foundation — copay assistance for insured patients at 400-500% FPL (866-316-7263)
• Bayer US Patient Assistance Foundation — free medication for uninsured qualifying patients
• Prescription Hope — medication access for $70/month

For a comprehensive list of patient savings resources, see how to help patients save money on Adempas.

Looking Ahead

Several developments may impact Adempas access in the coming months:

• Generic Riociguat commercial launch — timing remains uncertain but could occur in 2026
• Combination therapy guidelines — evolving evidence supports Adempas in combination with ERAs and prostacyclin analogs for PAH, which may increase prescribing volume
• Medicare negotiation eligibility — high-cost specialty drugs continue to be evaluated for Medicare price negotiation under the IRA

Final Thoughts

Adempas remains a critical therapy for PAH and the only FDA-approved medication for CTEPH. While supply is stable, the REMS program and specialty pharmacy infrastructure create real access challenges for patients. Providers play an essential role in smoothing this process by initiating specialty pharmacy coordination early, helping patients access financial assistance, and staying current on the availability landscape.

Use Medfinder for Providers to check availability and streamline your workflow. For clinical references, explore our guides on Adempas mechanism of action, side effects management, and helping patients find Adempas in stock.